Titan Pharmaceuticals — Investor Presentation (September 2017)
20 slides from Titan Pharmaceuticals's investor presentation, Sep 21, 2017
Slide 1: Corporate Presentation, September 2017
© 2017 TITAN PHARMACEUTICALS INC. | NASDAQ:TTNP CORPORATE PRESENTATION | SEPTEMBER 2017 TITAN PHARMACEUTICALS
Slide 2: Forward-Looking Statements
The presentation may contain “forward - looking statements” within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 . Reference is made in particular to the description of our plans and objectives for future operations, assumptions und
Slide 3: Company Snapshot
3 COMPANY SNAPSHOT ProNeura TM drug delivery platform provides long - term, continuous, non - fluctuating medication levels FDA approved Probuphine ® (buprenorphine) implant: six - month maintenance treatment of opioid addiction • C ommercial partnership with Braeburn Pharmaceuticals for U.S. and Ca
Slide 4: ProNeura Long-Term Drug Delivery Platform
4 • Active pharmaceutical ingredient (API) uniformly distributed throughout the ethylene vinyl acetate co - polymer (EVA) matrix • No reservoir, therefore no risk of drug dumping • Controlled rate of drug delivery and virtually 100% bioavailability EVA POLYMER API IMPLANT BLENDED & EXTRUDED PRONEURA
Slide 5: ProNeura Implant Administration
5 • Inserted subdermally in the inner side of the upper arm by a certified health care provider • Drug is released continuously into patient's body through the process of dissolution • Results in a stable level of medication in the blood, avoiding peaks and troughs of oral dosing • Round - the - clo
Slide 6: ProNeura Product Pipeline
6 CANDIDATE INDICATION DEVELOPMENT STAGE Probuphine ® (United States) Opioid Addiction Probuphine ® (European Union) Opioid Addiction Ropinirole Implant Parkinson’s Disease T3 Implant Hypothyroidism PRECLINICAL PHASE 1 PHASE 2 PHASE 3 MARKET PRECLINICAL PHASE 1 PHASE 2 PHASE 3 MARKET PHASE 2 PRECLIN
Slide 7: Other ProNeura Opportunities
7 Malaria Prophylaxis: • Collaboration with Walter Reed Army Institute of Research (WRAIR) and Southwest Research Institute (SWRI) • WRAIR interested in developing effective prophylactic treatments for armed forces personnel deployed to malaria endemic regions • Program currently funded by WRAIR and
Slide 8: Probuphine (Buprenorphine) Implant: FDA Approved for Opioid Addiction
8 PATIENTS Major epidemic: ~ 2.5 million people in U.S. affected TREATMENT Buprenorphine treatment is the gold standard ADVANTAGES Controls withdrawal symptoms and cravings without opioid euphoria; convenient outpatient treatment CHALLENGES Daily dosed formulations present various challenges: compli
Slide 9: Probuphine U.S. Commercialization
9 Partnership with Braeburn Pharma for U.S. and Canada * signed in December 2012 * Braeburn has sublicensed Canadian rights to Knight Therapeutics PROBUPHINE U.S. COMMERCIALIZATION Milestone payments Upfront: $15.75 million Approval Milestone: $15 million Sales Milestones: up to $165 million Tiered
Slide 10: Probuphine Full U.S. Commercial Launch Initiated Q1 2017
10 PROBUPHINE FULL U.S . COMMERCIAL LAUNCH INITIATED Q1 2017 • Braeburn launched with 60+ field sales force and medical support staff focusing on 80+ key U.S. treatment centers • Status: • 2,500+ health care providers certified under REMS program • 70+ payors indicated coverage intention, including
Slide 11: Probuphine Gaining Awareness
11 Recent media coverage includes: • New York Times • Fortune Magazine • CNBC • CBS • Drug Delivery Business News • WPIX - TV (New York, NY) • WMUR Channel 9 (Manchester, NH) • WHDT TV (Stuart, FL) Industry recognition: • Popular Science ‘Best of What’s New’ • Stevie Awards ‘Best New Product ’ PROBU
Slide 12: Probuphine OUS Commercialization Plans
12 Advancing OUS opportunities for regulatory approval and commercial licensing: • Progressing discussions with interested companies in EU and other select regions • March 2017: EMA confirmed eligibility for review and approval under centralized procedure • April 2017: EMA granted a pediatric indica
Slide 13: Parkinson's Disease (PD) Overview
Characterized by the loss of dopamine, which alters activity in the brain region impacting movement and motor function • Treated with drugs designed to replace or mimic dopamine in the brain • After several years of daily dosed pulsatile treatment , these drugs can lose benefit and trigger serious s
Slide 14: Parkinson's Disease Market and Burden
14 * GlobalData; **Parkinson’s Action Network, National Center for Health Statistics; “The Current and Projected Economic Burden of Parkinson’s Disease in the United States” Movement Disorders, March 2013 Based on information from Titan and other sources believed to be reliable and prepared exclusiv
Slide 15: ProNeura Parkinson's Disease Program
15 • Ropinirole (Requip®), a dopamine agonist marketed by GSK for PD • Evaluated in a Parkinsonian animal model using ProNeura drug delivery platform • Results presented in June 2015 - 19th International Congress of Parkinson's Disease and Movement Disorders • Sustained plasma ropinirole levels for
Slide 16: ProNeura Ropinirole Implant Program Status
2018 2017 16 Investigational New Drug Application cleared by FDA in late August 2017 PRONEURA ROPINIROLE IMPLANT PROGRAM STATUS Study completion is expected by the end of 2018 Data from the first patient cohort should be available in early 2018 following completion of the three - month treatment Pro
Slide 17: Opportunity in Hypothyroidism
Hypothyroidism: thyroid gland does not make enough hormone to meet the body’s need • Typical treatment: synthetic prohormone thyroxine (T4) given orally once a day • About 15% of patients have difficulty converting T4 to the active triiodothyronine ( T3); in those cases, oral T3 therapy is typically
Slide 18: Titan Pharmaceuticals Executive Management
18 TITAN PHARMACEUTICALS EXECUTIVE MANAGEMENT Marc Rubin, M.D. Executive Chairman & Director • 10 years with Titan • Former Head of Global R&D and member of the Board of Management at Bayer Pharma • Executive R&D and commercial responsibilities at GSK for 13 years • 26 years in the pharmaceutical in
Slide 19: Titan Pharmaceuticals Summary
ProNeura : Unique and compelling long - term drug delivery platform Probuphine : Only product on market to provide six - month, continuous, non - fluctuating blood levels of buprenorphine for maintenance treatment of opioid addiction Development Pipeline : ProNeura - based product candidates for Par
Slide 20: Thank You. Questions?
© 2017 TITAN PHARMACEUTICALS INC. | NASDAQ:TTNP CORPORATE PRESENTATION | SEPTEMBER 2017 THANK YOU. QUESTIONS?
Titan Pharmaceuticals — Investor Presentation (September 2017) on 6ix